CRISPR Therapeutics AG (CRSP)

Acerca de CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Al 3 de noviembre de 2026, la acción de CRISPR Therapeutics AG (CRSP) subió a $50.66, un alza de 1.35% (+$0.67) frente al cierre anterior. En la sesión, las acciones han operado entre $50.41 y $51.86. Eso ubica a CRSP en el tercio inferior de su rango de 52 semanas, de $44.12 a $63.45. CRISPR Therapeutics AG opera en el sector de biological products, (no diagnostic substances) y tiene una capitalización de mercado de aproximadamente $4.83 mil millones, con cerca de 409.3 mil acciones negociadas.

Últimas noticias de CRSP

• Crispr Therapeutics Reports Growing Casgevy Use Ahead of Key Pipeline Data, RBC SaysYahoo Finance· 3 nov, 11:54 a.m. ET
• CRSP's Q3 Loss Wider Than Expected, Sales Beat EstimatesYahoo Finance· 3 nov, 9:24 a.m. ET
• VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View RaisedYahoo Finance· 3 nov, 9:02 a.m. ET
• Vertex Yo-Yos On Mixed Third-Quarter Report, Light Guidance HikeYahoo Finance· 2 nov, 5:14 p.m. ET
• CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance· 2 nov, 4:55 p.m. ET
• Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reactionfool.com· 2 nov, 4:34 p.m. ET
• CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial ResultsYahoo Finance· 2 nov, 4:01 p.m. ETRMAT
• CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseYahoo Finance· 2 nov, 9:00 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de CRSP en un solo lugar? Crea una cuenta gratis →

• @tgamble3 yeah that next week data is the whole setup imo on $CRSP. I like how it is holding a base into the read, and the money on this one usually gets made in the runup, not on the headline. I post my full plan for it at https://bioswings.com. which part are you watching cl…

  @BiotechSwings· 3 nov, 11:05 a.m. ET

• $CRSP if good data next week doesn’t send this thing higher I think it’s literally just dead money at this point

  @tgamble3· 3 nov, 10:54 a.m. ET

• $CRSP 51.04 added 49.72 limit order in.

  @flabb· 3 nov, 10:39 a.m. ET

• $CRSP 51.31 added and still addin.g

  @flabb· 3 nov, 10:39 a.m. ET

• @burbs88 yeah that AMD read is exactly why I like holding through a base like this imo on $CRSP. trading it three times for a couple points each is one thing, sitting through the whole build is another. Casgevy doing 99M in a quarter now gives that chart something real underne…

  @BiotechSwings· 3 nov, 7:49 a.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →